Company turns to preclinical candidate in the same indication.

Adolor is nixing development of Entereg, its Phase III candidate for chronic opiate bowel dysfunction (OBD). In September, GlaxoSmithKline returned rights to Entereg covering various bowel dysfunction indications but retained rights to development in postoperative ileus (POI).

Adolor reports that it based its decision on an assessment of the cost and timeline for an additional Phase III study relative to the remaining commercial life of Entereg in OBD.

Instead, Adolor will focus on preclinical ADL7445, a peripherally acting mu-opioid receptor antagonist. The firm says that it is on track for for submission of an IND in mid-2009.

Entereg received FDA approval earlier this year for the management of POI following bowel resection surgery.

Previous articleGSK Gains Rights to Ligand’s Thrombopoietin Program with an Initial Payment of $5M
Next articleWyeth Takes Over Thiakis for $30M